221 related articles for article (PubMed ID: 33336229)
1. A Systematic Review on the Feasibility of Salivary Biomarkers for Alzheimer's Disease.
Bouftas M
J Prev Alzheimers Dis; 2021; 8(1):84-91. PubMed ID: 33336229
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for Alzheimer's Disease in Saliva: A Systematic Review.
Gleerup HS; Hasselbalch SG; Simonsen AH
Dis Markers; 2019; 2019():4761054. PubMed ID: 31191751
[TBL] [Abstract][Full Text] [Related]
3. A Method for Diagnosing Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels.
Lee M; Guo JP; Kennedy K; McGeer EG; McGeer PL
J Alzheimers Dis; 2017; 55(3):1175-1182. PubMed ID: 27792013
[TBL] [Abstract][Full Text] [Related]
4. Salivary beta amyloid protein levels are detectable and differentiate patients with Alzheimer's disease dementia from normal controls: preliminary findings.
Sabbagh MN; Shi J; Lee M; Arnold L; Al-Hasan Y; Heim J; McGeer P
BMC Neurol; 2018 Sep; 18(1):155. PubMed ID: 30257642
[TBL] [Abstract][Full Text] [Related]
5. Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer's Disease: Present and future applications.
Reale M; Gonzales-Portillo I; Borlongan CV
Brain Res; 2020 Jan; 1727():146535. PubMed ID: 31669827
[TBL] [Abstract][Full Text] [Related]
6. Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis.
Nijakowski K; Owecki W; Jankowski J; Surdacka A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256241
[TBL] [Abstract][Full Text] [Related]
7. Salivary biomarkers in Alzheimer's disease.
Tvarijonaviciute A; Zamora C; Ceron JJ; Bravo-Cantero AF; Pardo-Marin L; Valverde S; Lopez-Jornet P
Clin Oral Investig; 2020 Oct; 24(10):3437-3444. PubMed ID: 31989369
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
Müller EG; Edwin TH; Stokke C; Navelsaker SS; Babovic A; Bogdanovic N; Knapskog AB; Revheim ME
PLoS One; 2019; 14(8):e0221365. PubMed ID: 31430334
[TBL] [Abstract][Full Text] [Related]
9. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
10. The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia.
Santangelo R; Dell'Edera A; Sala A; Cecchetti G; Masserini F; Caso F; Pinto P; Leocani L; Falautano M; Passerini G; Martinelli V; Comi G; Perani D; Magnani G
Curr Alzheimer Res; 2019; 16(7):587-595. PubMed ID: 31345148
[TBL] [Abstract][Full Text] [Related]
11. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
[TBL] [Abstract][Full Text] [Related]
13. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
Blennow K; Zetterberg H
Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
[TBL] [Abstract][Full Text] [Related]
14. No association of salivary total tau concentration with Alzheimer's disease.
Ashton NJ; Ide M; Schöll M; Blennow K; Lovestone S; Hye A; Zetterberg H
Neurobiol Aging; 2018 Oct; 70():125-127. PubMed ID: 30007161
[TBL] [Abstract][Full Text] [Related]
15. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
[TBL] [Abstract][Full Text] [Related]
17. Antemortem CSF A
Baiardi S; Abu-Rumeileh S; Rossi M; Zenesini C; Bartoletti-Stella A; Polischi B; Capellari S; Parchi P
Ann Clin Transl Neurol; 2019 Feb; 6(2):263-273. PubMed ID: 30847359
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis.
Cui Y; Zhang H; Zhu J; Liao Z; Wang S; Liu W
Brain Sci; 2022 May; 12(5):. PubMed ID: 35624982
[TBL] [Abstract][Full Text] [Related]
19. Current State of Saliva Biomarkers for Aging and Alzheimer's Disease.
François M; Bull CF; Fenech MF; Leifert WR
Curr Alzheimer Res; 2019; 16(1):56-66. PubMed ID: 30345919
[TBL] [Abstract][Full Text] [Related]
20. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.
Bermejo-Pareja F; Antequera D; Vargas T; Molina JA; Carro E
BMC Neurol; 2010 Nov; 10():108. PubMed ID: 21047401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
